AEON Biopharma (NASDAQ:AEON) Trading Up 5% – Should You Buy?

AEON Biopharma, Inc. (NASDAQ:AEON)’s share price was up 5% during trading on Monday . The company traded as high as $1.45 and last traded at $1.26. Approximately 413,781 shares were traded during trading, an increase of 103% from the average daily volume of 203,605 shares. The stock had previously closed at $1.20.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Zacks Research upgraded AEON Biopharma to a “hold” rating in a research note on Tuesday, November 18th. HC Wainwright upgraded shares of AEON Biopharma to a “strong-buy” rating in a research report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, AEON Biopharma has an average rating of “Buy”.

AEON Biopharma Trading Up 5.0%

The firm has a 50 day moving average of $1.11 and a 200-day moving average of $0.94. The company has a market cap of $14.92 million, a P/E ratio of 7.00 and a beta of 0.72.

Institutional Trading of AEON Biopharma

An institutional investor recently raised its position in AEON Biopharma stock. XTX Topco Ltd grew its holdings in shares of AEON Biopharma, Inc. (NASDAQ:AEON) by 251.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 56,852 shares of the company’s stock after buying an additional 40,690 shares during the quarter. XTX Topco Ltd owned 0.48% of AEON Biopharma worth $63,000 at the end of the most recent reporting period. 22.78% of the stock is owned by institutional investors.

About AEON Biopharma

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.